97 related articles for article (PubMed ID: 34468989)
1. In-silico identification of frequently mutated genes and their co-enriched metabolic pathways associated with Prostate cancer progression.
Singh AN; Sharma N
Andrologia; 2021 Dec; 53(11):e14236. PubMed ID: 34468989
[TBL] [Abstract][Full Text] [Related]
2. In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer.
Baruah MM; Sharma N
Med Oncol; 2019 Apr; 36(5):43. PubMed ID: 30937635
[TBL] [Abstract][Full Text] [Related]
3. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
Fang E; Zhang X; Wang Q; Wang D
Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
[TBL] [Abstract][Full Text] [Related]
4. Environmental Phenol and Paraben Exposure Risks and Their Potential Influence on the Gene Expression Involved in the Prognosis of Prostate Cancer.
Alwadi D; Felty Q; Roy D; Yoo C; Deoraj A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409038
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analysis identified hub genes in prostate cancer tumorigenesis and metastasis.
Gu P; Yang D; Zhu J; Zhang M; He X
Math Biosci Eng; 2021 Apr; 18(4):3180-3196. PubMed ID: 34198380
[TBL] [Abstract][Full Text] [Related]
6. Identification of Potential Key Genes and Pathways in Enzalutamide-Resistant Prostate Cancer Cell Lines: A Bioinformatics Analysis with Data from the Gene Expression Omnibus (GEO) Database.
Zheng L; Dou X; Ma X; Qu W; Tang X
Biomed Res Int; 2020; 2020():8341097. PubMed ID: 32724813
[TBL] [Abstract][Full Text] [Related]
7. Identification of key genes and pathways in castrate-resistant prostate cancer by integrated bioinformatics analysis.
Wu YP; Ke ZB; Lin F; Wen YA; Chen S; Li XD; Chen SH; Sun XL; Huang JB; Zheng QS; Xue XY; Wei Y; Xu N
Pathol Res Pract; 2020 Oct; 216(10):153109. PubMed ID: 32853947
[TBL] [Abstract][Full Text] [Related]
8. Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data.
Xu N; Wu YP; Ke ZB; Liang YC; Cai H; Su WT; Tao X; Chen SH; Zheng QS; Wei Y; Xue XY
J Transl Med; 2019 Sep; 17(1):311. PubMed ID: 31533842
[TBL] [Abstract][Full Text] [Related]
9. Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis.
Sun J; Li S; Wang F; Fan C; Wang J
BMC Med Genet; 2019 Dec; 20(1):191. PubMed ID: 31791268
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
[TBL] [Abstract][Full Text] [Related]
11. Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
Ye Y; Li SL; Wang SY
PLoS One; 2018; 13(8):e0198055. PubMed ID: 30138363
[TBL] [Abstract][Full Text] [Related]
12. Identification of critical pathways and hub genes in
Sun J; Zhang K; Cai Z; Li K; Zhao C; Fan C; Wang J
Biomark Med; 2019 Jul; 13(10):831-840. PubMed ID: 31116024
[No Abstract] [Full Text] [Related]
13. Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis.
Wang Y; Wang J; Tang Q; Ren G
PLoS One; 2021; 16(2):e0247827. PubMed ID: 33630978
[TBL] [Abstract][Full Text] [Related]
14. Role of miR-452-5p in the tumorigenesis of prostate cancer: A study based on the Cancer Genome Atl(TCGA), Gene Expression Omnibus (GEO), and bioinformatics analysis.
Gao L; Zhang LJ; Li SH; Wei LL; Luo B; He RQ; Xia S
Pathol Res Pract; 2018 May; 214(5):732-749. PubMed ID: 29559248
[TBL] [Abstract][Full Text] [Related]
15. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
16. Identification of key genes in prostate cancer gene expression profile by bioinformatics.
Lu W; Ding Z
Andrologia; 2019 Feb; 51(1):e13169. PubMed ID: 30311263
[TBL] [Abstract][Full Text] [Related]
17. Identification of aberrantly methylated‑differentially expressed genes and gene ontology in prostate cancer.
Wang L; Wang B; Quan Z
Mol Med Rep; 2020 Feb; 21(2):744-758. PubMed ID: 31974616
[TBL] [Abstract][Full Text] [Related]
18. Pathway crosstalk analysis in prostate cancer based on protein-protein network data.
Li HY; Jin N; Han YP; Jin XF
Neoplasma; 2017; 64(1):22-31. PubMed ID: 27881001
[TBL] [Abstract][Full Text] [Related]
19. The Identification of Key Gene Expression Signature in Prostate Cancer.
Huang Y; Cao Q; Song Z; Ruan H; Wang K; Chen K; Zhang X
Crit Rev Eukaryot Gene Expr; 2020; 30(2):153-168. PubMed ID: 32558494
[TBL] [Abstract][Full Text] [Related]
20. Integrated Analysis Revealed Prognostic Factors for Prostate Cancer Patients.
Che H; Liu Y; Zhang M; Meng J; Feng X; Zhou J; Liang C
Med Sci Monit; 2019 Dec; 25():9991-10007. PubMed ID: 31876269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
